- Home
- HLXB vs THRD Comparison
HLXB vs THRD Comparison
Compare HLXB & THRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLXB
- THRD
- Stock Information
- Founded
- HLXB 2021
- THRD 2019
- Country
- HLXB United States
- THRD United States
- Employees
- HLXB N/A
- THRD N/A
- Industry
- HLXB
- THRD Biotechnology: Pharmaceutical Preparations
- Sector
- HLXB
- THRD Health Care
- Exchange
- HLXB NYSE
- THRD Nasdaq
- Market Cap
- HLXB 255.2M
- THRD 238.7M
- IPO Year
- HLXB 2024
- THRD 2022
- Fundamental
- Price
- HLXB $10.64
- THRD $5.43
- Analyst Decision
- HLXB
- THRD Hold
- Analyst Count
- HLXB 0
- THRD 3
- Target Price
- HLXB N/A
- THRD $5.00
- AVG Volume (30 Days)
- HLXB 99.0K
- THRD 254.9K
- Earning Date
- HLXB 01-01-0001
- THRD 08-07-2025
- Dividend Yield
- HLXB N/A
- THRD N/A
- EPS Growth
- HLXB N/A
- THRD N/A
- EPS
- HLXB 0.26
- THRD N/A
- Revenue
- HLXB N/A
- THRD N/A
- Revenue This Year
- HLXB N/A
- THRD N/A
- Revenue Next Year
- HLXB N/A
- THRD N/A
- P/E Ratio
- HLXB $41.63
- THRD N/A
- Revenue Growth
- HLXB N/A
- THRD N/A
- 52 Week Low
- HLXB $10.14
- THRD $3.18
- 52 Week High
- HLXB $11.59
- THRD $16.02
- Technical
- Relative Strength Index (RSI)
- HLXB N/A
- THRD 69.19
- Support Level
- HLXB N/A
- THRD $5.42
- Resistance Level
- HLXB N/A
- THRD $5.47
- Average True Range (ATR)
- HLXB 0.00
- THRD 0.05
- MACD
- HLXB 0.00
- THRD -0.01
- Stochastic Oscillator
- HLXB 0.00
- THRD 75.00
About HLXB HELIX ACQUISITION CORP. II
Helix Acquisition Corp II is a Blank check company.
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.